OncoMatch/Clinical Trials/NCT03802695
A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
Is NCT03802695 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies OrcaGraft (Orca-Q) for acute myeloid leukemia.
Treatment: OrcaGraft (Orca-Q) — This study will evaluate the safety, tolerability, and efficacy of engineered donor grafts ("OrcaGraft"/"Orca-Q") in participants undergoing allogeneic hematopoietic cell transplant (alloHCT) transplantation for hematologic malignancies.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Myeloid Leukemia
Myelodysplastic Syndrome
Acute Lymphoblastic Leukemia
Prior therapy
Cannot have received: allogeneic hematopoietic stem cell transplant
Prior alloHCT
Lab requirements
Kidney function
eGFR > 50 mL/min (MAC with tacrolimus) or > 30 mL/min (NMA/RIC or MAC without tacrolimus)
Liver function
Total bilirubin < 1.5x ULN (MAC) or < 3x ULN (NMA/RIC); ALT/AST < 3x ULN (MAC) or < 5x ULN (NMA/RIC)
Cardiac function
Ejection fraction ≥ 45% (MAC) or ≥ 40% (NMA/RIC)
eGFR > 50 mL/minute (MAC with tacrolimus) or > 30 mL/minute (NMA/RIC or MAC without tacrolimus) Cardiac ejection fraction ≥ 45 percent (MAC) or ≥ 40 percent (NMA/RIC) DLCO (adjusted for hemoglobin) ≥ 50 percent for MAC or ≥ 40 percent for NMA/RIC Liver function: Total bilirubin < 1.5x ULN (MAC) or < 3x ULN (NMA/RIC); ALT/AST < 3x ULN (MAC) or < 5x ULN (NMA/RIC)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- City of Hope · Duarte, California
- UC Davis · Sacramento, California
- Stanford Health Care · Stanford, California
- Moffitt Cancer Center · Tampa, Florida
- Emory University · Atlanta, Georgia
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify